To address the outstanding controversy and clear the pathway for therapeutic development to empower the NKG2D/NKG2D-L pathway for cancer immunotherapy, herein we utilized three mouse models to address the impact of the human sNKG2D-L, sMIC, on tumorigenesis and tumor progression. The gene discussed is KLRK1; the disease is neoplasm.